Sandoz Group (OTCMKTS:SDZNY) and Relmada Therapeutics (NASDAQ:RLMD) Financial Review

Sandoz Group (OTCMKTS:SDZNY) and Relmada Therapeutics (NASDAQ:RLMD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Earnings & Valuation

This table compares Sandoz Group and Relmada Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sandoz Group	$10.36 billion	3.00	$1.00 million	N/A	N/A
Relmada Therapeutics	N/A	N/A	-$79.98 million	($1.80)	-2.22

Sandoz Group has higher revenue and earnings than Relmada Therapeutics.

Insider & Institutional Ownership

0.1% of Sandoz Group shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 20.7% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Sandoz Group has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.

Profitability

This table compares Sandoz Group and Relmada Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sandoz Group	N/A	N/A	N/A
Relmada Therapeutics	N/A	-269.49%	-205.22%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Sandoz Group and Relmada Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sandoz Group	0	2	0	1	2.67
Relmada Therapeutics	1	0	1	0	2.00

Relmada Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 150.00%. Given Relmada Therapeutics’ higher possible upside, analysts clearly believe Relmada Therapeutics is more favorable than Sandoz Group.

Summary

Sandoz Group beats Relmada Therapeutics on 6 of the 11 factors compared between the two stocks.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

About Relmada Therapeutics

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.